Published in Cells Tissues Organs on November 03, 2010
c-Abl and Arg are activated in human primary melanomas, promote melanoma cell invasion via distinct pathways, and drive metastatic progression. Oncogene (2011) 1.15
Development of a highly selective c-Src kinase inhibitor. ACS Chem Biol (2012) 1.14
A roundabout way to cancer. Adv Cancer Res (2012) 1.11
The role of cytokines in breast cancer development and progression. J Interferon Cytokine Res (2014) 0.95
Therapeutic targeting of Neu1 sialidase with oseltamivir phosphate (Tamiflu®) disables cancer cell survival in human pancreatic cancer with acquired chemoresistance. Onco Targets Ther (2014) 0.92
Activation of abl family kinases in solid tumors. Genes Cancer (2012) 0.89
c-Abl-dependent molecular circuitry involving Smad5 and phosphatidylinositol 3-kinase regulates bone morphogenetic protein-2-induced osteogenesis. J Biol Chem (2013) 0.87
A phosphotyrosine switch determines the antitumor activity of ERβ. J Clin Invest (2014) 0.86
c-Abl and Arg induce cathepsin-mediated lysosomal degradation of the NM23-H1 metastasis suppressor in invasive cancer. Oncogene (2013) 0.82
Neuraminidase-1: a novel therapeutic target in multistage tumorigenesis. Oncotarget (2016) 0.77
Discovery of Bivalent Kinase Inhibitors via Enzyme-Templated Fragment Elaboration. ACS Med Chem Lett (2015) 0.76
The role of EphB4 and IGF-IR expression in breast cancer cells. Int J Clin Exp Pathol (2015) 0.76
c-Abl inhibits breast cancer tumorigenesis through reactivation of p53-mediated p21 expression. Oncotarget (2016) 0.75
Harnessing protein kinase A activation to induce mesenchymal-epithelial programs to eliminate chemoresistant, tumor-initiating breast cancer cells. Transl Cancer Res (2016) 0.75
The hallmarks of cancer. Cell (2000) 113.05
Molecular portraits of human breast tumours. Nature (2000) 94.14
Cancer statistics, 2009. CA Cancer J Clin (2009) 83.57
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A (2001) 71.82
The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell (2008) 46.08
Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A (2003) 34.68
The basics of epithelial-mesenchymal transition. J Clin Invest (2009) 32.82
Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer (2009) 18.53
TGFbeta in Cancer. Cell (2008) 17.44
Molecular definition of breast tumor heterogeneity. Cancer Cell (2007) 12.67
Stromal fibroblasts in cancer initiation and progression. Nature (2004) 11.69
Epithelial-mesenchymal transitions in development and pathologies. Curr Opin Cell Biol (2003) 11.12
TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science (2004) 10.23
Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer. Nat Rev Cancer (2006) 8.59
TGF-beta-induced epithelial to mesenchymal transition. Cell Res (2009) 7.88
A tense situation: forcing tumour progression. Nat Rev Cancer (2009) 7.80
Epithelial--mesenchymal and mesenchymal--epithelial transitions in carcinoma progression. J Cell Physiol (2007) 7.34
Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis. Cancer Cell (2008) 6.78
TGF-beta1 and Ha-Ras collaborate in modulating the phenotypic plasticity and invasiveness of epithelial tumor cells. Genes Dev (1996) 5.71
NF-kappaB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression. J Clin Invest (2004) 5.06
Phosphatidylinositol 3-kinase function is required for transforming growth factor beta-mediated epithelial to mesenchymal transition and cell migration. J Biol Chem (2000) 5.00
Regulation of the polarity protein Par6 by TGFbeta receptors controls epithelial cell plasticity. Science (2005) 4.70
Mechanism of TGF-beta signaling to growth arrest, apoptosis, and epithelial-mesenchymal transition. Curr Opin Cell Biol (2009) 3.94
TGF-beta and the Smad signaling pathway support transcriptomic reprogramming during epithelial-mesenchymal cell transition. Mol Biol Cell (2005) 3.75
Actions of TGF-beta as tumor suppressor and pro-metastatic factor in human cancer. Biochim Biophys Acta (2006) 3.64
p73 is regulated by tyrosine kinase c-Abl in the apoptotic response to DNA damage. Nature (1999) 3.55
Interaction of c-Abl and p73alpha and their collaboration to induce apoptosis. Nature (1999) 3.50
Cell size and invasion in TGF-beta-induced epithelial to mesenchymal transition is regulated by activation of the mTOR pathway. J Cell Biol (2007) 3.47
Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis. J Clin Invest (2004) 3.44
c-Abl is activated by growth factors and Src family kinases and has a role in the cellular response to PDGF. Genes Dev (1999) 3.09
Integrin beta 1 signaling is necessary for transforming growth factor-beta activation of p38MAPK and epithelial plasticity. J Biol Chem (2001) 3.04
Ataxia telangiectasia mutant protein activates c-Abl tyrosine kinase in response to ionizing radiation. Nature (1997) 2.98
The EphB4 receptor suppresses breast cancer cell tumorigenicity through an Abl-Crk pathway. Nat Cell Biol (2006) 2.87
Nuclear-cytoplasmic shuttling of C-ABL tyrosine kinase. Proc Natl Acad Sci U S A (1998) 2.73
Activation of Abl tyrosine kinases promotes invasion of aggressive breast cancer cells. Cancer Res (2006) 2.69
Activation of the Erk pathway is required for TGF-beta1-induced EMT in vitro. Neoplasia (2004) 2.60
Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase. Nat Med (2001) 2.51
Three-dimensional context regulation of metastasis. Clin Exp Metastasis (2008) 2.49
The Abl family kinases: mechanisms of regulation and signaling. Adv Cancer Res (2002) 2.49
Loss of TGF-beta type II receptor in fibroblasts promotes mammary carcinoma growth and invasion through upregulation of TGF-alpha-, MSP- and HGF-mediated signaling networks. Oncogene (2005) 2.35
The mouse c-abl locus: molecular cloning and characterization. Cell (1984) 2.33
Src phosphorylates Tyr284 in TGF-beta type II receptor and regulates TGF-beta stimulation of p38 MAPK during breast cancer cell proliferation and invasion. Cancer Res (2007) 2.28
Beta3 integrin and Src facilitate transforming growth factor-beta mediated induction of epithelial-mesenchymal transition in mammary epithelial cells. Breast Cancer Res (2006) 2.20
Integrin regulation of c-Abl tyrosine kinase activity and cytoplasmic-nuclear transport. Proc Natl Acad Sci U S A (1996) 2.19
STI571: targeting BCR-ABL as therapy for CML. Oncologist (2001) 2.15
Mechanisms of the epithelial-mesenchymal transition by TGF-beta. Future Oncol (2009) 1.90
Imatinib mesylate blocks a non-Smad TGF-beta pathway and reduces renal fibrogenesis in vivo. FASEB J (2005) 1.90
The TGF-beta paradox in human cancer: an update. Future Oncol (2009) 1.79
Aggressive breast cancer cells are dependent on activated Abl kinases for proliferation, anchorage-independent growth and survival. Oncogene (2007) 1.78
Circumventing resistance to kinase-inhibitor therapy. N Engl J Med (2006) 1.75
Modulation of the F-actin cytoskeleton by c-Abl tyrosine kinase in cell spreading and neurite extension. J Cell Biol (2002) 1.72
Inhibition of c-Abl tyrosine kinase activity by filamentous actin. J Biol Chem (2001) 1.71
Cox-2 inactivates Smad signaling and enhances EMT stimulated by TGF-beta through a PGE2-dependent mechanisms. Carcinogenesis (2008) 1.69
Therapeutic targeting of the focal adhesion complex prevents oncogenic TGF-beta signaling and metastasis. Breast Cancer Res (2009) 1.67
Inhibition of cell migration by Abl family tyrosine kinases through uncoupling of Crk-CAS complexes. J Biol Chem (2001) 1.65
Grb2 binding to Tyr284 in TbetaR-II is essential for mammary tumor growth and metastasis stimulated by TGF-beta. Carcinogenesis (2008) 1.62
The cytostatic function of c-Abl is controlled by multiple nuclear localization signals and requires the p53 and Rb tumor suppressor gene products. EMBO J (1996) 1.60
Transforming growth factor-beta in breast cancer: too much, too late. Breast Cancer Res (2009) 1.51
Altered TAB1:I kappaB kinase interaction promotes transforming growth factor beta-mediated nuclear factor-kappaB activation during breast cancer progression. Cancer Res (2008) 1.47
Fibulin-5 initiates epithelial-mesenchymal transition (EMT) and enhances EMT induced by TGF-beta in mammary epithelial cells via a MMP-dependent mechanism. Carcinogenesis (2008) 1.45
Abl tyrosine kinases regulate cell-cell adhesion through Rho GTPases. Proc Natl Acad Sci U S A (2007) 1.43
Transforming growth factor-beta can suppress tumorigenesis through effects on the putative cancer stem or early progenitor cell and committed progeny in a breast cancer xenograft model. Cancer Res (2007) 1.42
TGF-beta signaling in breast cancer. Ann N Y Acad Sci (2006) 1.39
STI571: a paradigm of new agents for cancer therapeutics. J Clin Oncol (2002) 1.38
p130Cas is required for mammary tumor growth and transforming growth factor-beta-mediated metastasis through regulation of Smad2/3 activity. J Biol Chem (2009) 1.37
Activated c-Abl tyrosine kinase in malignant solid tumors. Oncogene (2008) 1.28
c-Abl phosphorylates Dok1 to promote filopodia during cell spreading. J Cell Biol (2004) 1.26
Transforming growth factor beta activation of c-Abl is independent of receptor internalization and regulated by phosphatidylinositol 3-kinase and PAK2 in mesenchymal cultures. J Biol Chem (2006) 1.24
Treatment for chronic myelogenous leukemia: the long road to imatinib. J Clin Invest (2007) 1.22
Role of transforming growth factor beta in breast carcinogenesis. Lancet Oncol (2004) 1.22
Imatinib mesylate (Gleevec) in advanced breast cancer-expressing C-Kit or PDGFR-beta: clinical activity and biological correlations. Ann Oncol (2008) 1.21
Increased C-CRK proto-oncogene expression is associated with an aggressive phenotype in lung adenocarcinomas. Oncogene (2003) 1.20
Activated Abl kinase inhibits oncogenic transforming growth factor-beta signaling and tumorigenesis in mammary tumors. FASEB J (2009) 1.20
A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancer. Breast Cancer Res Treat (2005) 1.19
c-Abl: activation and nuclear targets. Cell Death Differ (2000) 1.19
Abl tyrosine kinases modulate cadherin-dependent adhesion upstream and downstream of Rho family GTPases. Cell Cycle (2007) 1.16
Oncogenic activation of c-Abl in non-small cell lung cancer cells lacking FUS1 expression: inhibition of c-Abl by the tumor suppressor gene product Fus1. Oncogene (2007) 1.15
Modulation of DNA damage-induced apoptosis by cell adhesion is independently mediated by p53 and c-Abl. Proc Natl Acad Sci U S A (2003) 1.12
Activated c-Abl is degraded by the ubiquitin-dependent proteasome pathway. Curr Biol (2001) 1.12
Emergence of the phosphoinositide 3-kinase-Akt-mammalian target of rapamycin axis in transforming growth factor-β-induced epithelial-mesenchymal transition. Cells Tissues Organs (2010) 1.11
The tyrosine kinase Abl is required for Src-transforming activity in mouse fibroblasts and human breast cancer cells. Oncogene (2007) 1.11
The use of cystatin C to inhibit epithelial-mesenchymal transition and morphological transformation stimulated by transforming growth factor-beta. Breast Cancer Res (2005) 1.10
DNA mismatch repair-dependent activation of c-Abl/p73alpha/GADD45alpha-mediated apoptosis. J Biol Chem (2008) 1.07
Nuclear tyrosine kinases: from Abl to WEE1. Curr Opin Cell Biol (1996) 1.07
Cytoplasmic c-Abl provides a molecular 'Rheostat' controlling carcinoma cell survival and invasion. Oncogene (2003) 1.02
PGE2 receptor EP2 mediates the antagonistic effect of COX-2 on TGF-beta signaling during mammary tumorigenesis. FASEB J (2009) 1.02
A phase II study of imatinib mesylate and capecitabine in metastatic breast cancer: Southwest Oncology Group Study 0338. Clin Breast Cancer (2008) 1.02
Tumor necrosis factor alpha-induced apoptosis requires p73 and c-ABL activation downstream of RB degradation. Mol Cell Biol (2004) 1.00
Tyrosine kinase inhibitor STI571 enhances thyroid cancer cell motile response to Hepatocyte Growth Factor. Oncogene (2001) 0.99
Role for c-Abl and p73 in the radiation response of male germ cells. Oncogene (2001) 0.99
Targeted TGF-beta chemotherapies: friend or foe in treating human malignancies? Expert Rev Anticancer Ther (2007) 0.98
X-linked inhibitor of apoptosis protein and its E3 ligase activity promote transforming growth factor-{beta}-mediated nuclear factor-{kappa}B activation during breast cancer progression. J Biol Chem (2009) 0.98
Role of c-Abl kinase in DNA mismatch repair-dependent G2 cell cycle checkpoint arrest responses. J Biol Chem (2008) 0.97
A phase I trial of docetaxel/estramustine/imatinib in patients with hormone-refractory prostate cancer. Clin Genitourin Cancer (2007) 0.96
Smaddening complexity: the role of Smad3 in epithelial-myofibroblast transition. Cells Tissues Organs (2010) 0.92
Death by Abl: a matter of location. Curr Top Dev Biol (2004) 0.92
A phase II trial of imatinib mesylate in patients with biochemical relapse of prostate cancer after definitive local therapy. BJU Int (2006) 0.92
The tyrosine kinase inhibitor imatinib fails to inhibit pancreatic cancer progression. Cancer Lett (2006) 0.88
Imatinib mesylate for the treatment of chronic myeloid leukemia. Expert Rev Anticancer Ther (2008) 0.88
Regulation of cellular transformation by oncogenic and normal Abl kinases. J Biochem (2007) 0.84
Development of human protein reference database as an initial platform for approaching systems biology in humans. Genome Res (2003) 14.79
Apoptotic cells, through transforming growth factor-beta, coordinately induce anti-inflammatory and suppress pro-inflammatory eicosanoid and NO synthesis in murine macrophages. J Biol Chem (2006) 2.47
TGF-β upregulates miR-181a expression to promote breast cancer metastasis. J Clin Invest (2012) 2.44
Pigment epithelium-derived factor in idiopathic pulmonary fibrosis: a role in aberrant angiogenesis. Am J Respir Crit Care Med (2004) 2.42
Src phosphorylates Tyr284 in TGF-beta type II receptor and regulates TGF-beta stimulation of p38 MAPK during breast cancer cell proliferation and invasion. Cancer Res (2007) 2.28
Beta3 integrin and Src facilitate transforming growth factor-beta mediated induction of epithelial-mesenchymal transition in mammary epithelial cells. Breast Cancer Res (2006) 2.20
The pathophysiology of epithelial-mesenchymal transition induced by transforming growth factor-beta in normal and malignant mammary epithelial cells. J Mammary Gland Biol Neoplasia (2010) 2.12
The Six1 homeoprotein induces human mammary carcinoma cells to undergo epithelial-mesenchymal transition and metastasis in mice through increasing TGF-beta signaling. J Clin Invest (2009) 2.01
Mechanisms of the epithelial-mesenchymal transition by TGF-beta. Future Oncol (2009) 1.90
The TGF-beta paradox in human cancer: an update. Future Oncol (2009) 1.79
Fibulins 3 and 5 antagonize tumor angiogenesis in vivo. Cancer Res (2006) 1.69
Cox-2 inactivates Smad signaling and enhances EMT stimulated by TGF-beta through a PGE2-dependent mechanisms. Carcinogenesis (2008) 1.69
Therapeutic targeting of the focal adhesion complex prevents oncogenic TGF-beta signaling and metastasis. Breast Cancer Res (2009) 1.67
Transforming growth factor-β and the hallmarks of cancer. Cell Signal (2010) 1.66
Down-regulation of epithelial cadherin is required to initiate metastatic outgrowth of breast cancer. Mol Biol Cell (2011) 1.66
SPARC inhibits epithelial cell proliferation in part through stimulation of the transforming growth factor-beta-signaling system. Mol Biol Cell (2003) 1.63
Grb2 binding to Tyr284 in TbetaR-II is essential for mammary tumor growth and metastasis stimulated by TGF-beta. Carcinogenesis (2008) 1.62
Cross-talk between ERK and p38 MAPK mediates selective suppression of pro-inflammatory cytokines by transforming growth factor-beta. J Biol Chem (2002) 1.53
Deconstructing the mechanisms and consequences of TGF-β-induced EMT during cancer progression. Cell Tissue Res (2011) 1.53
Altered TAB1:I kappaB kinase interaction promotes transforming growth factor beta-mediated nuclear factor-kappaB activation during breast cancer progression. Cancer Res (2008) 1.47
Fibulin-5 initiates epithelial-mesenchymal transition (EMT) and enhances EMT induced by TGF-beta in mammary epithelial cells via a MMP-dependent mechanism. Carcinogenesis (2008) 1.45
Krüppel-like factor 4 inhibits tumorigenic progression and metastasis in a mouse model of breast cancer. Neoplasia (2011) 1.39
Noncanonical TGF-β signaling during mammary tumorigenesis. J Mammary Gland Biol Neoplasia (2011) 1.38
p130Cas is required for mammary tumor growth and transforming growth factor-beta-mediated metastasis through regulation of Smad2/3 activity. J Biol Chem (2009) 1.37
Role of transforming growth factor-beta in cancer progression. Future Oncol (2006) 1.34
Identification and characterization of regulator of G protein signaling 4 (RGS4) as a novel inhibitor of tubulogenesis: RGS4 inhibits mitogen-activated protein kinases and vascular endothelial growth factor signaling. Mol Biol Cell (2004) 1.29
Transcriptional and translational regulation of TGF-beta production in response to apoptotic cells. J Immunol (2008) 1.26
Fibulin-5 antagonizes vascular endothelial growth factor (VEGF) signaling and angiogenic sprouting by endothelial cells. DNA Cell Biol (2004) 1.20
Activated Abl kinase inhibits oncogenic transforming growth factor-beta signaling and tumorigenesis in mammary tumors. FASEB J (2009) 1.20
Cystatin C antagonizes transforming growth factor beta signaling in normal and cancer cells. Mol Cancer Res (2004) 1.19
The relevance of the TGF-β Paradox to EMT-MET programs. Cancer Lett (2013) 1.18
Homeoprotein Six1 increases TGF-beta type I receptor and converts TGF-beta signaling from suppressive to supportive for tumor growth. Cancer Res (2010) 1.16
Transcriptome analysis of endothelial cell gene expression induced by growth on matrigel matrices: identification and characterization of MAGP-2 and lumican as novel regulators of angiogenesis. Angiogenesis (2007) 1.15
Epithelial to mesenchymal transition promotes breast cancer progression via a fibronectin-dependent STAT3 signaling pathway. J Biol Chem (2013) 1.15
Repo-man controls a protein phosphatase 1-dependent threshold for DNA damage checkpoint activation. Curr Biol (2010) 1.13
The use of cystatin C to inhibit epithelial-mesenchymal transition and morphological transformation stimulated by transforming growth factor-beta. Breast Cancer Res (2005) 1.10
NetSlim: high-confidence curated signaling maps. Database (Oxford) (2011) 1.09
Lysyl oxidase contributes to mechanotransduction-mediated regulation of transforming growth factor-β signaling in breast cancer cells. Neoplasia (2011) 1.09
Microfibril-associate glycoprotein-2 (MAGP-2) promotes angiogenic cell sprouting by blocking notch signaling in endothelial cells. Microvasc Res (2008) 1.08
Fibulin-5 function during tumorigenesis. Future Oncol (2005) 1.05
Targeted inactivation of β1 integrin induces β3 integrin switching, which drives breast cancer metastasis by TGF-β. Mol Biol Cell (2013) 1.02
PGE2 receptor EP2 mediates the antagonistic effect of COX-2 on TGF-beta signaling during mammary tumorigenesis. FASEB J (2009) 1.02
Targeted TGF-beta chemotherapies: friend or foe in treating human malignancies? Expert Rev Anticancer Ther (2007) 0.98
X-linked inhibitor of apoptosis protein and its E3 ligase activity promote transforming growth factor-{beta}-mediated nuclear factor-{kappa}B activation during breast cancer progression. J Biol Chem (2009) 0.98
Role of TGF-β and the tumor microenvironment during mammary tumorigenesis. Gene Expr (2011) 0.97
In vivo dual substrate bioluminescent imaging. J Vis Exp (2011) 0.97
Fibulin-2 and fibulin-5 alterations in tsk mice associated with disorganized hypodermal elastic fibers and skin tethering. J Invest Dermatol (2004) 0.96
Sox4, EMT programs, and the metastatic progression of breast cancers: mastering the masters of EMT. Breast Cancer Res (2013) 0.96
Novel bone morphogenetic protein signaling through Smad2 and Smad3 to regulate cancer progression and development. FASEB J (2013) 0.95
Fibroblast growth factor receptor splice variants are stable markers of oncogenic transforming growth factor β1 signaling in metastatic breast cancers. Breast Cancer Res (2014) 0.94
Upregulated WAVE3 expression is essential for TGF-β-mediated EMT and metastasis of triple-negative breast cancer cells. Breast Cancer Res Treat (2013) 0.93
β3 integrin-EGF receptor cross-talk activates p190RhoGAP in mouse mammary gland epithelial cells. Mol Biol Cell (2011) 0.90
Fibulin-5 promotes wound healing in vivo. J Am Coll Surg (2004) 0.86
Epithelial-mesenchymal transition in tumor metastasis: a method to the madness. Future Oncol (2009) 0.86
Cloning of a novel signaling molecule, AMSH-2, that potentiates transforming growth factor beta signaling. BMC Cell Biol (2004) 0.85
Preclinical efficacy of cystatin C to target the oncogenic activity of transforming growth factor Beta in breast cancer. Transl Oncol (2009) 0.84
Fibromodulin suppresses nuclear factor-kappaB activity by inducing the delayed degradation of IKBA via a JNK-dependent pathway coupled to fibroblast apoptosis. J Biol Chem (2010) 0.79
TGF-beta in cancer and other diseases. Future Oncol (2006) 0.77
Colorectal cancer in the cotton top tamarin (Saguinus oedipus): how do they evade liver metastasis? Dig Dis Sci (2010) 0.76